PLPL
Plandaí Biotechnology, Inc.0.0001
+0.0000+0%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
No earnings call transcript available
Key Stats
Market Cap
4.49MP/E (TTM)
-Basic EPS (TTM)
0.00Dividend Yield
0%Recent Filings
10-Q
Q1 FY2017 results
Plandai Biotechnology doubled revenues to $80,820 in Q1 FY2017 ended September 30, 2016, from $40,831 y/y, thanks to Phytofare sales alongside timber and on-site store receipts, yet operating loss narrowed just 18% to $(719,195) as expenses fell to $800,015 from $919,996. Net loss hit $(1,110,452) after $481,939 interest expense—up sharply y/y from $309,880—while derivative gains offset some pain. Cash climbed to $22,091 on $163,000 convertible notes, despite $(159,275) operating burn; debt towers at $14.9M current, covenant breaches reclassifying Land Bank loans. Shares issued for services and conversions swelled count 30%. Disclosure controls ineffective. Debt overhang looms large.
10-K
FY2016 results
Plandaí Biotechnology posted FY2016 revenue of $298k, up 221% y/y from $93k, yet still deep in the red with a $4.4M net loss after non-cash stock comp eased expenses from FY2015's $9.6M hit. Q4 2015 hailstorm crippled tea harvest, slashing Phytofare extract output and sales momentum into FY2016 despite factory ops since early 2015. Expenses plunged on lower stock grants, but $1.8M interest and $1.0M derivative hits dragged results. Debt towers at $14.1M current, cash burned $1.1M on ops. No guidance disclosed. Auditors flag going concern doubts from losses and liquidity crunch.
8-K
Share increase, cannabis spin-off
Plandai shareholders approved increasing authorized shares from 500 million to 1 billion on September 9, with Nevada filing on September 15. Board then greenlit a 25 million share dividend—25% of subsidiary Cannabis Biosciences—payable September 30 to spin it off publicly soon. Shareholders get cannabis extract licensing play.
10-Q
Q3 FY2016 results
Plandaí Biotechnology posted Q3 revenue of $100K, up sharply from $22K y/y yet still dwarfed by $825K expenses, yielding a $725K operating loss versus $5.99M last year; nine-month revenue doubled to $198K but YTD operating loss narrowed to $2.29M from $8.37M, driven by payroll cuts after one-time stock bonuses. Net loss widened to $1.09M from interest, exceeding operating by $370K mainly from $375K interest expense. Cash dwindled to $8K amid $829K operating burn, offset by $865K financing including stock sales and debt; $13.9M notes loom current due to covenant breaches. South Africa drives all revenue. Revenue remains tiny.
10-Q
Q2 FY2016 results
Plandaí Biotechnology posted Q2 FY2016 revenue of $50,553, down 25% y/y from $67,101 amid a 27% Rand depreciation, yet expenses fell 39% to $749,333, trimming operating loss to $698,780 from $1,158,898. Six-month revenue slid 40% y/y to $91,473 (all South Africa), with YTD operating loss at $1,578,009; net loss of $1,926,537 reflects higher interest expense of $633,502 versus $250,518 prior year. Cash dwindled to $13,506 on $438,003 operating burn, offset by $475,371 financing including $400,000 debt; $13.3M notes payable loom current due to covenant breaches. No free cash flow disclosed. Debt weighs heavy.
IPO
Employees
Sector
Industry
BQST
BioQuest Corp.
0.51+0.00
CNDA
Concord Acquisition Corp II
11.42+0.00
GPLB
GREEN PLANET BIOENGINEERING CO
0.01+0.00
PELI
Pelican Acquisition Corporation
10.16+0.02
PLAOF
-
12.00+0.00
PLMJF
Plum Acquisition Corp. III
11.55+0.00
PLSH
Panacea Life Sciences Holdings,
0.09+0.00
PLTYF
PLASTEC TECHNOLOGIES LTD
0.02+0.00
PLUR
Pluri Inc.
2.96-0.06
PNPL
Pineapple, Inc.
0.13+0.00